|
|
CyPA |
|
Vaxjo ID |
305 |
|
Vaccine Adjuvant Name |
CyPA |
|
Alternative Names |
Cyclophilin A |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
Cyclophilin A (CyPA) is a host protein that can promote dendritic cell maturation and subsequent innate immune responses when incorporated into an HIV-1 Gag protein. It is evaluated as a genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Rat |
|
Components |
Cyclophilin A (CyPA) can promote dendritic cell maturation and the subsequent innate immune response when incorporated into an HIV-1 Gag protein to circumvent the resistance of dendritic cells to HIV-1 infection |
|
Structure |
The paper mentions "site-directed mutagenesis in CyPA, including active site residues H54Q and F60A", indicating a protein structure. |
|
Preparation |
Evaluated using a DNA vaccine with single or dual expression cassettes. |
|
Function |
Previous research showed that Cyclophilin A (CyPA) helps dendritic cells overcome HIV-1 resistance by promoting their maturation when fused with HIV-1 Gag protein. Building on this, the study hypothesized that CyPA could enhance the immune response to an HIV-1 Gag vaccine. Experiments in mice demonstrated that CyPA specifically boosted Gag-targeted cellular immunity—especially when co-expressed with Gag in a dual DNA vaccine—leading to a strong, broad, and long-lasting T cell response focused on cellular immunity rather than antibodies. Mutations disrupting CyPA’s active site greatly reduced this adjuvant effect, indicating that CyPA’s enhancement depends on its specific interaction with Gag. Overall, CyPA acts as a potent, specific genetic adjuvant to improve HIV-1 Gag vaccine efficacy. |
| Related Vaccine(s) |
|
| References |
Hou et al., 2016: Hou J, Zhang Q, Liu Z, Wang S, Li D, Liu C, Liu Y, Shao Y. Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice. Human vaccines & immunotherapeutics. 2016; 12(2); 545-553. [PubMed: 26305669].
|
|
